Evolocumab, a PCSK9 inhibitor, is not a direct HF treatment but plays a supportive role by improving lipid profiles and reducing atherosclerotic cardiovascular risk in HF patients with underlying ischemic heart disease. This evidence concerns the gene PCSK9 and hydrops fetalis.